Circulating molecular markers in pancreatic cancer: Ready for clinical use?

Future Oncology

Volumn 9, Issue 2, 2013, Pages 141-144

  Gall, Tamara Mh ^a   Frampton, Adam E ^a   Krell, Jonathan ^a   Castellano, Leandro ^a   Jiao, Long R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

biomarker; cell free DNA; circulating tumor cells; miRNA; pancreatic cancer

Indexed keywords

MICRORNA; MOLECULAR MARKER;

CANCER MORTALITY; CANCER SURVIVAL; CELL FREE SYSTEM; CIRCULATING TUMOR CELL; DNA DETERMINATION; DNA EXTRACTION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FINE NEEDLE ASPIRATION BIOPSY; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR VOLUME;

DNA; HUMANS; MICRORNAS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874029281     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.187     Document Type: Review

References (27)

1. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319), 1114-1117 (2010).
2. Yamaguchi T, Shirai Y, Nakamura N et al. Usefulness of brush cytology combined with pancreatic juice cytology in the diagnosis of pancreatic cancer: significance of pancreatic juice cytology after brushing. Pancreas 41(8), 1225-1229 (2012).
3. Hewitt MJ, Mcphail MJW, Possamai L et al. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: A meta-analysis. Gastrointest. Endosc. 75(2), 319-331 (2012).
4. Barton JG, Bois JP, Sarr MG et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J. Gastrointest. Surg. 13(11), 2050-2058 (2009).
5. Hata S, Sakamoto Y, Yamamoto Y et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann. Surg. Oncol. 19(2), 636-641 (2012).
6. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 14(3), 146-149 (1869).
7. Cen P, Ni X, Yang J, Graham DY, Li M. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim. Biophys. Acta 1826(2), 350-356 (2012).
8. Riethdorf S, Fritsche H, Müller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin. Cancer Res. 13(3), 920-928 (2007).
9. Jiao LR, Apostolopoulos C, Jacob J et al. Unique localization of circulating tumor cells in patients with hepatic metastases. J. Clin. Oncol. 27(36), 6160-6165 (2009).
10. Shaw JA, Brown J, Coombes RC et al. Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. Biomarkers Med. 5(1), 87-91 (2011).
11. Iwanicki-Caron et al. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. Am. J. Gastro. 108(1), 152-155 (2013).
12. Ren C, Han C, Zhang J et al. Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. Cancer Biol. Ther. 12(8), 700-706 (2011).
13. De Albuquerque A, Kubisch I, Breier G et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: A feasibility study. Oncology 82(1), 3-10 (2012).
14. Yu M, Ting DT, Stott SL et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487(7408), 510-513 (2012).
15. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 148(1), 349-361 (2012).
16. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker: A critical appraisal of the literature. Clin. Chim. Acta 411(21-22), 1611-1624 (2010).
17. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659-1665 (2001).
18. Stroun M, Maurice P, Vasioukhin V et al. The origin and mechanism of circulating DNA. Ann. NY Acad. Sci. 906, 161-168 (2000).
19. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41(2), 276-282 (2001).
20. Dabritz J, Preston R, Hanfler J, Oettle H. Follow-up study of Kras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas 38(5), 534-541 (2009).
21. Dabritz J, Preston R, Hanfler J, Oettle H. Kras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer. Pancreas 41(2), 323-325 (2012).
22. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur. J. Surg. Oncol. 36(7), 657-662 (2010).
23. Park JW, Baek IH, Kim YT. Preliminary study analyzing the methylated genes in the plasma of patients with pancreatic cancer. Scand. J. Surg. 101(1), 38-44 (2012).
24. Liggett T, Melnikov A, Yi QL et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116(7), 1674-1680 (2010).
25. Kong X, Du Y, Wang G et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci. 56(2), 602-609 (2010).
26. Wang P, Zhuang L, Zhang J et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol. Oncol. doi:10.1016/j.molonc.2012.10.011 (2012) (Epub ahead of print).
27. Bauer AS, Keller A, Costello E et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 7(4), e34151 (2012).